Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Culver who wrote (1042)	8/19/1998 9:05:00 PM
From: Harold Lehman	Read Replies (3) of 1501

Received my proxy and annual report today. It was mailed out on Aug.17. There are two proposals, numbers 3&4 which I am voting against. Proposal 3 is basically for the approval of stock options previously granted to insiders and also allows them to change the terms of these options. Very nice. The stock goes down and they can lower their exercise price, just what we shareholders need. Proposal 4 is a special resolution that allows the authorized share capital to increase from 50 million shares to 100 million shares. Somehow I get the idea that it's not in order to be able to split the stock due to rapidly increasing share value. Two words come to mind: Fire Sale. I don't like the idea of a 30-40 million share private placement at 25 cents or less per share. Thus, I feel very strongly in voting against these two proposals. Did any of you read the annual report? Very disappointing. A problem we all thought had been solved very early this year has cropped up again. It's Inflazyme's chronic inability to synthesize enough Apanol, or IPL 576, the anti-asthma compound. I was told earlier this year that it was no problem any more. I feel just as slimed out from this as after listening to Clinton's admission last night. Sure it's a new compound, but they've had a lot of time to get this ironed out. I even get the feeling that it's a problem that presently has not been solved. Maybe this explains the wall of silence to us smaller shareholders. Another aspect of this that really bothers me is that they did not say specifically how much animal testing has been successfully completed, and whether IPL 576 is still completely nontoxic. And then there's Cortecs and the TB diagnostic test. Someone's been lying to me. Phil Goodwin, project manager of this work at Cortecs, told me back in early January that there should be good news a few weeks to a few months from that day I spoke with him. Has anyone here seen or heard the good news? Also Inflazyme was supposed to receive the test kits months ago. And why should Inflazyme have to complete the testing? I thought Cortecs was going to handle that. Another thing that irked me about the annual report. There was no mention of any progress or anything going on whatsoever involving the anticancer compounds licensed out to Supergen. Congratulations management! You're really on top of things. And what's the problem with the company's website? Show some professionalism and get it working. Harold Lehman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next